Prevalence, incidence and risk factors of tamoxifen‐related non‐alcoholic fatty liver disease: A systematic review and meta‐analysis
Background & Aims Tamoxifen is associated with an increased risk of developing fatty liver. The aim of this systematic review and meta‐analysis was to evaluate the prevalence and incidence of fatty liver developed after tamoxifen treatment in breast cancer patients. Methods A systematic search o...
Gespeichert in:
| Veröffentlicht in: | Liver international 2020-06, Vol.40 (6), p.1344-1355 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1355 |
|---|---|
| container_issue | 6 |
| container_start_page | 1344 |
| container_title | Liver international |
| container_volume | 40 |
| creator | Lee, Bora Jung, Eun‐Ae Yoo, Jeong‐Ju Kim, Sang Gyune Lee, Cheon‐Beom Kim, Young Seok Jeong, Soung Won Jang, Jae Young Lee, Sae Hwan Kim, Hong Soo Jun, Baek Gyu Kim, Young Don Cheon, Gab Jin |
| description | Background & Aims
Tamoxifen is associated with an increased risk of developing fatty liver. The aim of this systematic review and meta‐analysis was to evaluate the prevalence and incidence of fatty liver developed after tamoxifen treatment in breast cancer patients.
Methods
A systematic search of PubMed (Medline), EMBASE, OVID Medline, the Cochrane Library and other databases was performed for this review. The s obtained from the search were reviewed by two investigators who chose manuscripts for full‐text review. The event rates were calculated with a random‐effects model and quality‐effects model.
Results
The search yielded 165 references. Of these, 24 were included in the quantitative summary. We analysed the data of a total of 6,962 patients treated with tamoxifen and 975 patients not treated with tamoxifen. The prevalence of fatty liver among patients with breast cancer taking tamoxifen was 40.25 per 100 patients and the incidence rate was 12.37 per 100 person‐years. The incidence of fatty liver was much higher in the tamoxifen group than in the control group [incidence rate ratio: 3.12, 95% CI (confidence interval): 2.05‐4.75, I2 = 61%], regardless of region. The main risk factors were body mass index (BMI) [hazard ratio (HR): 1.15, 95% CI: 1.09‐1.22] and hypercholesterolaemia (HR: 1.01, 95% CI: 1.00‐1.02).
Conclusion
The use of tamoxifen was associated with increased risks in the incidence and prevalence of fatty liver, especially in patients with high BMI and hypercholesterolaemia. |
| doi_str_mv | 10.1111/liv.14434 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2377343477</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2377343477</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3534-994bd8ceb55d88c2df5f99196d0d41d34fa99e02667a2bb48efa6d2f513a8f813</originalsourceid><addsrcrecordid>eNp1kcFu1DAQhi1ERcvCgRdAlriAxLZx7CR2b1UFpdJKcACu0cQeCxcnLra3JTfOnHhGnqROt-0BCR_GM9I3_4zmJ-QFqw5ZeUfeXR0yIbh4RA6Y6OSa15w9fshrvk-epnRRVUyphj0h-7xmXSVVc0B-f4p4BR4njW-pm7QzS0phMjS69J1a0DnERIOlGcbw01mc_v76E9FDRkOnsFTgdfgWvNMFz3mmZR-M1LiEkPCYntA0p4wj5EKUcQ6vbweMmGHpnsDPyaVnZM-CT_j87l-RL-_ffT79sN58PDs_PdmsNW-4WCslBiM1Dk1jpNS1sY1ViqnWVEYww4UFpbCq27aDehiERAutqW3DOEgrGV-R1zvdyxh-bDHlfnRJo_cwYdimvuZdx8sxS1yRV_-gF2Eby76FElUnRcuaRfDNjtIxpBTR9pfRjRDnnlX9YlBfDtLfGlTYl3eK22FE80DeO1KAox1w7TzO_1fqN-dfd5I3OAOfEQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2407846151</pqid></control><display><type>article</type><title>Prevalence, incidence and risk factors of tamoxifen‐related non‐alcoholic fatty liver disease: A systematic review and meta‐analysis</title><source>Wiley Online Library - AutoHoldings Journals</source><creator>Lee, Bora ; Jung, Eun‐Ae ; Yoo, Jeong‐Ju ; Kim, Sang Gyune ; Lee, Cheon‐Beom ; Kim, Young Seok ; Jeong, Soung Won ; Jang, Jae Young ; Lee, Sae Hwan ; Kim, Hong Soo ; Jun, Baek Gyu ; Kim, Young Don ; Cheon, Gab Jin</creator><creatorcontrib>Lee, Bora ; Jung, Eun‐Ae ; Yoo, Jeong‐Ju ; Kim, Sang Gyune ; Lee, Cheon‐Beom ; Kim, Young Seok ; Jeong, Soung Won ; Jang, Jae Young ; Lee, Sae Hwan ; Kim, Hong Soo ; Jun, Baek Gyu ; Kim, Young Don ; Cheon, Gab Jin</creatorcontrib><description>Background & Aims
Tamoxifen is associated with an increased risk of developing fatty liver. The aim of this systematic review and meta‐analysis was to evaluate the prevalence and incidence of fatty liver developed after tamoxifen treatment in breast cancer patients.
Methods
A systematic search of PubMed (Medline), EMBASE, OVID Medline, the Cochrane Library and other databases was performed for this review. The s obtained from the search were reviewed by two investigators who chose manuscripts for full‐text review. The event rates were calculated with a random‐effects model and quality‐effects model.
Results
The search yielded 165 references. Of these, 24 were included in the quantitative summary. We analysed the data of a total of 6,962 patients treated with tamoxifen and 975 patients not treated with tamoxifen. The prevalence of fatty liver among patients with breast cancer taking tamoxifen was 40.25 per 100 patients and the incidence rate was 12.37 per 100 person‐years. The incidence of fatty liver was much higher in the tamoxifen group than in the control group [incidence rate ratio: 3.12, 95% CI (confidence interval): 2.05‐4.75, I2 = 61%], regardless of region. The main risk factors were body mass index (BMI) [hazard ratio (HR): 1.15, 95% CI: 1.09‐1.22] and hypercholesterolaemia (HR: 1.01, 95% CI: 1.00‐1.02).
Conclusion
The use of tamoxifen was associated with increased risks in the incidence and prevalence of fatty liver, especially in patients with high BMI and hypercholesterolaemia.</description><identifier>ISSN: 1478-3223</identifier><identifier>EISSN: 1478-3231</identifier><identifier>DOI: 10.1111/liv.14434</identifier><identifier>PMID: 32170895</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Body mass ; Body mass index ; Body size ; Breast cancer ; Confidence intervals ; Fatty liver ; incidence ; Liver ; Liver diseases ; Meta-analysis ; Risk analysis ; risk factor ; Risk factors ; Searching ; Systematic review ; Tamoxifen</subject><ispartof>Liver international, 2020-06, Vol.40 (6), p.1344-1355</ispartof><rights>2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><rights>2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><rights>2020 John Wiley & Sons A/S</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3534-994bd8ceb55d88c2df5f99196d0d41d34fa99e02667a2bb48efa6d2f513a8f813</citedby><cites>FETCH-LOGICAL-c3534-994bd8ceb55d88c2df5f99196d0d41d34fa99e02667a2bb48efa6d2f513a8f813</cites><orcidid>0000-0003-3966-9302 ; 0000-0001-8694-777X ; 0000-0001-8320-5914 ; 0000-0003-4693-9542 ; 0000-0002-7802-0381 ; 0000-0001-9003-9862 ; 0000-0003-2855-6011 ; 0000-0001-5335-752X ; 0000-0002-7113-3623 ; 0000-0002-6322-5712</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fliv.14434$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fliv.14434$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32170895$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Bora</creatorcontrib><creatorcontrib>Jung, Eun‐Ae</creatorcontrib><creatorcontrib>Yoo, Jeong‐Ju</creatorcontrib><creatorcontrib>Kim, Sang Gyune</creatorcontrib><creatorcontrib>Lee, Cheon‐Beom</creatorcontrib><creatorcontrib>Kim, Young Seok</creatorcontrib><creatorcontrib>Jeong, Soung Won</creatorcontrib><creatorcontrib>Jang, Jae Young</creatorcontrib><creatorcontrib>Lee, Sae Hwan</creatorcontrib><creatorcontrib>Kim, Hong Soo</creatorcontrib><creatorcontrib>Jun, Baek Gyu</creatorcontrib><creatorcontrib>Kim, Young Don</creatorcontrib><creatorcontrib>Cheon, Gab Jin</creatorcontrib><title>Prevalence, incidence and risk factors of tamoxifen‐related non‐alcoholic fatty liver disease: A systematic review and meta‐analysis</title><title>Liver international</title><addtitle>Liver Int</addtitle><description>Background & Aims
Tamoxifen is associated with an increased risk of developing fatty liver. The aim of this systematic review and meta‐analysis was to evaluate the prevalence and incidence of fatty liver developed after tamoxifen treatment in breast cancer patients.
Methods
A systematic search of PubMed (Medline), EMBASE, OVID Medline, the Cochrane Library and other databases was performed for this review. The s obtained from the search were reviewed by two investigators who chose manuscripts for full‐text review. The event rates were calculated with a random‐effects model and quality‐effects model.
Results
The search yielded 165 references. Of these, 24 were included in the quantitative summary. We analysed the data of a total of 6,962 patients treated with tamoxifen and 975 patients not treated with tamoxifen. The prevalence of fatty liver among patients with breast cancer taking tamoxifen was 40.25 per 100 patients and the incidence rate was 12.37 per 100 person‐years. The incidence of fatty liver was much higher in the tamoxifen group than in the control group [incidence rate ratio: 3.12, 95% CI (confidence interval): 2.05‐4.75, I2 = 61%], regardless of region. The main risk factors were body mass index (BMI) [hazard ratio (HR): 1.15, 95% CI: 1.09‐1.22] and hypercholesterolaemia (HR: 1.01, 95% CI: 1.00‐1.02).
Conclusion
The use of tamoxifen was associated with increased risks in the incidence and prevalence of fatty liver, especially in patients with high BMI and hypercholesterolaemia.</description><subject>Body mass</subject><subject>Body mass index</subject><subject>Body size</subject><subject>Breast cancer</subject><subject>Confidence intervals</subject><subject>Fatty liver</subject><subject>incidence</subject><subject>Liver</subject><subject>Liver diseases</subject><subject>Meta-analysis</subject><subject>Risk analysis</subject><subject>risk factor</subject><subject>Risk factors</subject><subject>Searching</subject><subject>Systematic review</subject><subject>Tamoxifen</subject><issn>1478-3223</issn><issn>1478-3231</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp1kcFu1DAQhi1ERcvCgRdAlriAxLZx7CR2b1UFpdJKcACu0cQeCxcnLra3JTfOnHhGnqROt-0BCR_GM9I3_4zmJ-QFqw5ZeUfeXR0yIbh4RA6Y6OSa15w9fshrvk-epnRRVUyphj0h-7xmXSVVc0B-f4p4BR4njW-pm7QzS0phMjS69J1a0DnERIOlGcbw01mc_v76E9FDRkOnsFTgdfgWvNMFz3mmZR-M1LiEkPCYntA0p4wj5EKUcQ6vbweMmGHpnsDPyaVnZM-CT_j87l-RL-_ffT79sN58PDs_PdmsNW-4WCslBiM1Dk1jpNS1sY1ViqnWVEYww4UFpbCq27aDehiERAutqW3DOEgrGV-R1zvdyxh-bDHlfnRJo_cwYdimvuZdx8sxS1yRV_-gF2Eby76FElUnRcuaRfDNjtIxpBTR9pfRjRDnnlX9YlBfDtLfGlTYl3eK22FE80DeO1KAox1w7TzO_1fqN-dfd5I3OAOfEQ</recordid><startdate>202006</startdate><enddate>202006</enddate><creator>Lee, Bora</creator><creator>Jung, Eun‐Ae</creator><creator>Yoo, Jeong‐Ju</creator><creator>Kim, Sang Gyune</creator><creator>Lee, Cheon‐Beom</creator><creator>Kim, Young Seok</creator><creator>Jeong, Soung Won</creator><creator>Jang, Jae Young</creator><creator>Lee, Sae Hwan</creator><creator>Kim, Hong Soo</creator><creator>Jun, Baek Gyu</creator><creator>Kim, Young Don</creator><creator>Cheon, Gab Jin</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3966-9302</orcidid><orcidid>https://orcid.org/0000-0001-8694-777X</orcidid><orcidid>https://orcid.org/0000-0001-8320-5914</orcidid><orcidid>https://orcid.org/0000-0003-4693-9542</orcidid><orcidid>https://orcid.org/0000-0002-7802-0381</orcidid><orcidid>https://orcid.org/0000-0001-9003-9862</orcidid><orcidid>https://orcid.org/0000-0003-2855-6011</orcidid><orcidid>https://orcid.org/0000-0001-5335-752X</orcidid><orcidid>https://orcid.org/0000-0002-7113-3623</orcidid><orcidid>https://orcid.org/0000-0002-6322-5712</orcidid></search><sort><creationdate>202006</creationdate><title>Prevalence, incidence and risk factors of tamoxifen‐related non‐alcoholic fatty liver disease: A systematic review and meta‐analysis</title><author>Lee, Bora ; Jung, Eun‐Ae ; Yoo, Jeong‐Ju ; Kim, Sang Gyune ; Lee, Cheon‐Beom ; Kim, Young Seok ; Jeong, Soung Won ; Jang, Jae Young ; Lee, Sae Hwan ; Kim, Hong Soo ; Jun, Baek Gyu ; Kim, Young Don ; Cheon, Gab Jin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3534-994bd8ceb55d88c2df5f99196d0d41d34fa99e02667a2bb48efa6d2f513a8f813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Body mass</topic><topic>Body mass index</topic><topic>Body size</topic><topic>Breast cancer</topic><topic>Confidence intervals</topic><topic>Fatty liver</topic><topic>incidence</topic><topic>Liver</topic><topic>Liver diseases</topic><topic>Meta-analysis</topic><topic>Risk analysis</topic><topic>risk factor</topic><topic>Risk factors</topic><topic>Searching</topic><topic>Systematic review</topic><topic>Tamoxifen</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Bora</creatorcontrib><creatorcontrib>Jung, Eun‐Ae</creatorcontrib><creatorcontrib>Yoo, Jeong‐Ju</creatorcontrib><creatorcontrib>Kim, Sang Gyune</creatorcontrib><creatorcontrib>Lee, Cheon‐Beom</creatorcontrib><creatorcontrib>Kim, Young Seok</creatorcontrib><creatorcontrib>Jeong, Soung Won</creatorcontrib><creatorcontrib>Jang, Jae Young</creatorcontrib><creatorcontrib>Lee, Sae Hwan</creatorcontrib><creatorcontrib>Kim, Hong Soo</creatorcontrib><creatorcontrib>Jun, Baek Gyu</creatorcontrib><creatorcontrib>Kim, Young Don</creatorcontrib><creatorcontrib>Cheon, Gab Jin</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Liver international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Bora</au><au>Jung, Eun‐Ae</au><au>Yoo, Jeong‐Ju</au><au>Kim, Sang Gyune</au><au>Lee, Cheon‐Beom</au><au>Kim, Young Seok</au><au>Jeong, Soung Won</au><au>Jang, Jae Young</au><au>Lee, Sae Hwan</au><au>Kim, Hong Soo</au><au>Jun, Baek Gyu</au><au>Kim, Young Don</au><au>Cheon, Gab Jin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevalence, incidence and risk factors of tamoxifen‐related non‐alcoholic fatty liver disease: A systematic review and meta‐analysis</atitle><jtitle>Liver international</jtitle><addtitle>Liver Int</addtitle><date>2020-06</date><risdate>2020</risdate><volume>40</volume><issue>6</issue><spage>1344</spage><epage>1355</epage><pages>1344-1355</pages><issn>1478-3223</issn><eissn>1478-3231</eissn><abstract>Background & Aims
Tamoxifen is associated with an increased risk of developing fatty liver. The aim of this systematic review and meta‐analysis was to evaluate the prevalence and incidence of fatty liver developed after tamoxifen treatment in breast cancer patients.
Methods
A systematic search of PubMed (Medline), EMBASE, OVID Medline, the Cochrane Library and other databases was performed for this review. The s obtained from the search were reviewed by two investigators who chose manuscripts for full‐text review. The event rates were calculated with a random‐effects model and quality‐effects model.
Results
The search yielded 165 references. Of these, 24 were included in the quantitative summary. We analysed the data of a total of 6,962 patients treated with tamoxifen and 975 patients not treated with tamoxifen. The prevalence of fatty liver among patients with breast cancer taking tamoxifen was 40.25 per 100 patients and the incidence rate was 12.37 per 100 person‐years. The incidence of fatty liver was much higher in the tamoxifen group than in the control group [incidence rate ratio: 3.12, 95% CI (confidence interval): 2.05‐4.75, I2 = 61%], regardless of region. The main risk factors were body mass index (BMI) [hazard ratio (HR): 1.15, 95% CI: 1.09‐1.22] and hypercholesterolaemia (HR: 1.01, 95% CI: 1.00‐1.02).
Conclusion
The use of tamoxifen was associated with increased risks in the incidence and prevalence of fatty liver, especially in patients with high BMI and hypercholesterolaemia.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>32170895</pmid><doi>10.1111/liv.14434</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-3966-9302</orcidid><orcidid>https://orcid.org/0000-0001-8694-777X</orcidid><orcidid>https://orcid.org/0000-0001-8320-5914</orcidid><orcidid>https://orcid.org/0000-0003-4693-9542</orcidid><orcidid>https://orcid.org/0000-0002-7802-0381</orcidid><orcidid>https://orcid.org/0000-0001-9003-9862</orcidid><orcidid>https://orcid.org/0000-0003-2855-6011</orcidid><orcidid>https://orcid.org/0000-0001-5335-752X</orcidid><orcidid>https://orcid.org/0000-0002-7113-3623</orcidid><orcidid>https://orcid.org/0000-0002-6322-5712</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1478-3223 |
| ispartof | Liver international, 2020-06, Vol.40 (6), p.1344-1355 |
| issn | 1478-3223 1478-3231 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2377343477 |
| source | Wiley Online Library - AutoHoldings Journals |
| subjects | Body mass Body mass index Body size Breast cancer Confidence intervals Fatty liver incidence Liver Liver diseases Meta-analysis Risk analysis risk factor Risk factors Searching Systematic review Tamoxifen |
| title | Prevalence, incidence and risk factors of tamoxifen‐related non‐alcoholic fatty liver disease: A systematic review and meta‐analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T13%3A14%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevalence,%20incidence%20and%20risk%20factors%20of%20tamoxifen%E2%80%90related%20non%E2%80%90alcoholic%20fatty%20liver%20disease:%20A%20systematic%20review%20and%20meta%E2%80%90analysis&rft.jtitle=Liver%20international&rft.au=Lee,%20Bora&rft.date=2020-06&rft.volume=40&rft.issue=6&rft.spage=1344&rft.epage=1355&rft.pages=1344-1355&rft.issn=1478-3223&rft.eissn=1478-3231&rft_id=info:doi/10.1111/liv.14434&rft_dat=%3Cproquest_cross%3E2377343477%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2407846151&rft_id=info:pmid/32170895&rfr_iscdi=true |